High throughput P450 inhibition screens in early drug discovery.

[1]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[2]  S. O'Brien,et al.  Greater than the sum of its parts: combining models for useful ADMET prediction. , 2005, Journal of medicinal chemistry.

[3]  R. Dolle,et al.  Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity , 2005 .

[4]  D. Braun.  Mainstreaming microfluidics: diffusing microfluidics technology in the marketplace. , 2003, Pharmacogenomics.

[5]  D. Greenblatt,et al.  Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  C L Crespi,et al.  Fluorometric High‐Throughput Screening for Inhibitors of Cytochrome P450 , 2000, Annals of the New York Academy of Sciences.

[7]  A. Nomeir,et al.  Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[8]  S. Clarke.  In vitro assessment of human cytochrome P450. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  I. Kariv,et al.  Development of a Miniaturized 384-Well High Throughput Screen for the Detection of Substrates of Cytochrome P450 2D6 and 3A4 Metabolism , 2001, Journal of biomolecular screening.

[10]  C. F. Wilkinson,et al.  Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. , 1977, Biochemical pharmacology.

[11]  R. Riley,et al.  Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. , 2004, Drug discovery today. Technologies.

[12]  A. P. Koley,et al.  CO Binding Kinetics of Human Cytochrome P450 3A4 , 1995, The Journal of Biological Chemistry.

[13]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[14]  Andrew M Davis,et al.  Predictive ADMET studies, the challenges and the opportunities. , 2004, Current opinion in chemical biology.

[15]  D. Huryn,et al.  Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates , 2003, Journal of biomolecular screening.

[16]  David Raunig,et al.  In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[17]  R Scott Obach,et al.  Drug metabolism and drug interactions: application and clinical value of in vitro models. , 2003, Current drug metabolism.

[18]  Stewart B Kirton,et al.  Prediction of binding modes for ligands in the cytochromes P450 and other heme‐containing proteins , 2005, Proteins.

[19]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[20]  W. Woggon,et al.  Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4). , 2003, Bioorganic & medicinal chemistry letters.

[21]  Honglu Zhang,et al.  A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Chris de Graaf,et al.  Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.

[23]  Sean Ekins,et al.  Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[24]  B. Hammock,et al.  Design, synthesis and evaluation of novel P450 fluorescent probes bearing α-cyanoether , 2003 .

[25]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[26]  H. Welker,et al.  Clinical Pharmacokinetics of Mibefradil , 1998, Clinical pharmacokinetics.

[27]  C. Masimirembwa,et al.  In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. , 2001, Combinatorial chemistry & high throughput screening.

[28]  R. Obach,et al.  Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8 , 2005, Journal of clinical pharmacology.

[29]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[30]  C. Campañá,et al.  Clinically Significant Drug Interactions with Cyclosporin An Update , 1996, Clinical pharmacokinetics.

[31]  Peter D J Grootenhuis,et al.  Progress in computational methods for the prediction of ADMET properties. , 2002, Current opinion in drug discovery & development.

[32]  A. Sedman.  Cimetidine-drug interactions. , 1984, The American journal of medicine.

[33]  C. Masimirembwa,et al.  Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[34]  Riley Rj,et al.  Cellular models for ADMET predictions and evaluation of drug-drug interactions. , 2004 .

[35]  R J Riley,et al.  Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[36]  György M Keseru,et al.  A neural network based virtual screening of cytochrome P450 3A4 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[37]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[38]  A. D. Rodrigues,et al.  The Potential for CYP2D6 Inhibition Screening Using a Novel Scintillation Proximity Assay-Based Approach , 2001, Journal of biomolecular screening.

[39]  O. Trubetskoy,et al.  Highly Miniaturized Formats for In Vitro Drug Metabolism Assays Using Vivid® Fluorescent Substrates and Recombinant Human Cytochrome P450 Enzymes , 2005, Journal of biomolecular screening.

[40]  Sean Ekins,et al.  KOHONEN MAPS FOR PREDICTION OF BINDING TO HUMAN CYTOCHROME P450 3A4 , 2004, Drug Metabolism and Disposition.

[41]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[42]  Kiyomi Ito,et al.  Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.

[43]  D. Greenblatt,et al.  In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.

[44]  I. Kariv,et al.  Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. , 2002, Combinatorial chemistry & high throughput screening.

[45]  A. Rettie,et al.  Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. , 1998, Biochemistry.

[46]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[47]  Stewart B Kirton,et al.  In silico methods for predicting ligand binding determinants of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[48]  M. Hutzler,et al.  Predicting drug-drug interactions in drug discovery: where are we now and where are we going? , 2005, Current opinion in drug discovery & development.

[49]  Jonathan J. Burbaum,et al.  Miniaturization technologies in HTS: how fast, how small, how soon? , 1998 .

[50]  Riley Rj.  The potential pharmacological and toxicological impact of P450 screening. , 2001 .

[51]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[52]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[53]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[54]  D A. Dunn,et al.  Challenges and solutions to ultra-high-throughput screening assay miniaturization: submicroliter fluid handling. , 2000, Drug discovery today.

[55]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[56]  R. Weaver.  Assessment of drug-drug interactions: concepts and approaches , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[57]  Jing Lin,et al.  The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. , 2003, Current topics in medicinal chemistry.

[58]  M. Schulz,et al.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. , 2003, Die Pharmazie.

[59]  Bradley L Ackermann,et al.  Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. , 2002, Current topics in medicinal chemistry.

[60]  J. Wölcke,et al.  Miniaturized HTS technologies - uHTS. , 2001, Drug discovery today.

[61]  Current application of mass spectrometry to combinatorial chemistry. , 2002, Analytical chemistry.

[62]  D. Thakker,et al.  High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. , 2004, Journal of pharmaceutical sciences.

[63]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[64]  G. Dresser,et al.  A basic conceptual and practical overview of interactions with highly prescribed drugs. , 2002, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[65]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[66]  R. J. Riley,et al.  Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.

[67]  Han van de Waterbeemd,et al.  High-throughput and in silico techniques in drug metabolism and pharmacokinetics. , 2002 .

[68]  R. Weaver,et al.  Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[69]  C. Decker,et al.  Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. , 2001, Current opinion in chemical biology.

[70]  A. D. Rodrigues,et al.  Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. , 1994, Analytical biochemistry.

[71]  D. Nelson,et al.  Introductory remarks on human CYPs , 2002, Drug metabolism reviews.